Home
Search:
1146 feeds
357 categories
0 articles (<24 hours)
29 registered users

Use the Mobile version
Mobile

Follow our Twitter feed

View our Linkpartners
Links

Username:
Password:

Register | Retrieve

General


RSS FeedsNovartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD
(WorldNews Switzerland)

 
 

15 april 2019 23:40:11

 
Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD
(WorldNews Switzerland)
 


By 2020, over 1.5 million people in the US are likely to have wet AMD, the leading cause of blindness in industrialized countries Filing is based on Phase III data from the HAWK and HARRIER trials for brolucizumab Novartis used a priority review voucher to expedite review of brolucizumab in the US and, if approved by FDA, anticipates launching by the end of 2019 Basel, April 15, 2019- Novartis announced that the US Food and Drug Administration (FDA) accepted the company`s Biologics License Application (BLA) for brolucizumab (RTH258) for the treatment of wet age-related macular degeneration (AMD), also known as neovascular AMD, or nAMD. Seeking to make brolucizumab available as quickly as...


 
8 viewsCategory: General > Europe > Switzerland
 
Kenya`s Lawrence Cherono wins men`s Boston Marathon in sprint to tape
(WorldNews Switzerland)
Swisscom Blockchain AG Onboards New Chief Executive Officer
(WorldNews Switzerland)
 
 
blog comments powered by Disqus


Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Nachrichten